WealthTrust Axiom’s Abeona Therapeutics ABEO Stock Holding History

WealthTrust Axiom’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-760	Closed	-$3K	–	248
2022 Q2	$3K	Hold	760	–	–	﹤0.01%	249
2022 Q1	$5K	Hold	760	–	–	﹤0.01%	268
2021 Q4	$6K	Hold	760	–	–	﹤0.01%	268
2021 Q3	$21K	Hold	760	–	–	0.01%	254
2021 Q2	$29K	Hold	760	–	–	0.01%	264
2021 Q1	$35K	Buy	+760	New	+$41.9K	0.01%	250

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WealthTrust Axiom's ABEO Position: Q3 2022 in Review

WealthTrust Axiom sold out of Abeona Therapeutics (ABEO) in Q3 2022, closing a stake of 760 shares — an estimated $3K sold.

WealthTrust Axiom first reported a position in ABEO in Q1 2021 and held it in 6 quarters. The position peaked at $35K in Q1 2021. 24 funds tracked by Wall St. Rank hold ABEO as of Q3 2022.

WealthTrust Axiom reported no remaining Abeona Therapeutics position as of Q3 2022 after selling out during the quarter.
WealthTrust Axiom sold 760 Abeona Therapeutics shares in Q3 2022, an estimated $3K.
WealthTrust Axiom first reported a position in Abeona Therapeutics in Q1 2021 and held it in 6 quarters.
WealthTrust Axiom's Abeona Therapeutics position peaked at $35K in Q1 2021.
24 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2022.

Based on WealthTrust Axiom's 13F filing for Q3 2022, filed 3 Nov 2022.